Interleukin 28 is a potential therapeutic target for sepsis
Interleukin 28 is a potential therapeutic target for sepsis
复制标题
白细胞介素 28 是脓毒症的潜在治疗靶点
DOI：
10.1016/j.clim.2019.05.012
复制
发表时间：
2019-08-01
影响因子：
8.6
通讯作者：
Cao, Ju
中科院分区：
文献类型：
--
作者：
Luo, Qin;Liu, Yi;Cao, Ju
寻找治疗脓毒症的新靶点势在必行。我们在此报告，细胞因子IL-28(干扰素-20)水平在临床和实验性脓毒症中升高。中和IL-28可保护小鼠免受盲肠结扎和穿孔(CLP)所致的致死性脓毒症，这与改善细菌清除和增加中性粒细胞的渗透有关。相反，在CLP诱导的脓毒症模型中，给予重组IL-28加重了死亡率，促进了细菌异化，限制了中性粒细胞的募集。本研究将IL-28定义为脓毒症过程中的一种有害介质，并确定了脓毒症免疫治疗的潜在治疗靶点。
Identification of new therapeutic targets for the treatment of sepsis is imperative. We report here that cytokine IL-28 (IFN-20 levels were elevated in clinical and experimental sepsis. Neutralization of IL-28 protected mice from lethal sepsis induced by cecal ligation and puncture (CLP), which was associated with improved bacterial clearance and enhanced neutrophil infiltration. Conversely, administration of recombinant IL-28 aggravated mortality, facilitated bacterial dissimilation and limited neutrophil recruitment, in the model of sepsis induced by CLP. This study defines IL-28 as a detrimental mediator during sepsis and identifies a potential therapeutic target for the immune therapy in sepsis.